Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

For instance, the approval of Verona Pharma’s Ohtuvayre by the U.S. Food and Drug Administration (FDA) provided a much-needed non-steroid inhaled treatment option for patients with chronic obstructive ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in the U.S., Canada, Europe, and Japan before Akeso's news broke. The company ...

Credit: Getty Images The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products ...

Verona Murphy spent her first full day in the Dáil this week and had her work cut out for her as tension rose, causing her to suspend the meeting twice. Failing to pass the position of Taoiseach back ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...